- Long-acting insulin is currently dominated by Sanofi's Lantus. Thanks to once daily dosing, Lantus sales totaled nearly $8 billion in 2013.
- AntriaBio is taking a unique approach to developing the world's first once weekly insulin therapy.
- Moving from once daily to once weekly dosing has the potential to capture 30-40% of the $10 billion long-acting insulin market.
- We believe AntriaBio shares are attractive today based on the potential for AB101.
There are no Related articles on ANTB.
There are no Transcripts on ANTB.
We currently have no Breaking News on this stock.
There are no StockTalks on this stock yet.
ANTB vs. ETF Alternatives
AntriaBio is a biopharmaceutical company focused on developing novel therapeutic products for the diabetes market. Our development strategy combines FDA-approved pharmaceutical agents with our proprietary delivery technology. Our lead product candidate is AB101, an injectable once-a-week basal... More
Other News & PR